Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.